DOCSLIB.ORG

The 22Nd Annual Norman P. Salzman Memorial Awards and Symposium in Basic and Clinical Virology Monday, November 9, 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The 22Nd Annual Norman P. Salzman Memorial Awards and Symposium in Basic and Clinical Virology Monday, November 9, 2020 The 22nd Annual Norman P. Salzman Memorial Awards and Symposium in Basic and Clinical Virology Monday, November 9, 2020 Due to the COVID-19 pandemic, caused by SARS-CoV-2, this event is fully virtual for the first time in the symposium's history. Norman P. Salzman, Ph.D. Dr. Norman P. Salzman was a noted pioneer in the field of molecular virology and a founding editor of the Journal of Virology. In 1967 Dr. Salzman became Chief of the Laboratory of Biology of Viruses at the National Institute of Allergy and Infectious Diseases (NIAID) where he encouraged independence and excellence among his Fellows. Upon his retirement from NIH in 1986, Dr. Salzman moved to Georgetown University to head the Laboratory of Molecular Retrovirology, where he began his research on AIDS. This important work continued after he moved his laboratory in 1994 to the Frederick Cancer and Development Center (SAIC Program), where Dr. Salzman was appointed Director of an innovative mentoring program for post-doctoral fellows. Dr. Salzman was among the first to characterize viral mRNAs and to visualize replicating viral DNA. During his distinguished career at NIH, Dr. Salzman made many important and innovative contributions to our basic understanding of the replication of poliovirus, vaccinia virus, polyoma virus, SV40 virus and BK virus. Dr. Salzman’s studies on human immunodeficiency virus led to his discovery that ongoing evolution of viral quasi-species, despite combination antiretroviral therapy, characterized the relationship among viruses from different compartments and elucidated novel mechanisms of antiretroviral drug resistance. This work set the stage for todays’ work focusing on the role of viral reservoirs and challenges to HIV cure. Dr. Salzman’s memorable achievements in virology are paralleled by the recognition that his laboratory was a training ground for many young scientists, several of whom went on to become laboratory or section Chiefs at the NIH, and others to hold leadership positions in academia and industry all over the world. Six have been elected to the National Academy of Sciences and one received the Nobel Prize. - H. Clifford Lane, M.D., NIAID Norman P. Salzman Memorial Awards and Twenty-Second Annual Symposium in Basic and Clinical Virology 9:00 – 9:10 AM Welcome Nihal Altan-Bonnet, Ph.D., NHLBI, NIH 9:10 – 9:20 AM A Noble Salute Harvey J. Alter, M.D., MACP, Distinguished NIH Scientist Emeritus, 2020 Nobel Laureate in Physiology or Medicine 9:20 – 9:25 AM Foundation for the National Institutes of Health Maria C. Freire, Ph.D., President and Executive Director, FNIH 9:25 – 10:00 AM Keynote Presentation Perspectives for active and passive immunization after Covid-19 acceleration Rino Rappuoli, Ph.D., GlaxoSmithKline (GSK) 10:00 – 10:35 AM Coronaviruses: Old and New Susan R. Weiss, Ph.D., University of Pennsylvania 10:35 – 10:50 AM Tribute to Dr. Norman P. Salzman Marshall Bloom, M.D, Rocky Mountain Laboratories, NIAID, NIH 10:50 – 11:00 AM Presentation of the 2020 Norman P. Salzman Memorial Awards in Basic and Clinical Virology Lenore Salzman 11:00 – 11:25 AM Postdoctoral Fellow Award Lecture SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness Kizzmekia S. Corbett, Ph.D., NIAID, NIH 11:25 – 12:00 PM Human metapneumovirus: How it moves from cell to cell Rebecca Dutch, Ph.D., University of Kentucky 12:00 – 1:00 PM Lunch Break 1:00 – 1:35 PM Flavivirus Structure – Maybe a lot more complicated (interesting!) than we thought Richard Kuhn, Ph.D., Purdue University 1:35 – 2:00 PM Graduate Student Award Lecture Neutralization of Nipah virus via antibody-mediated targeting of the fusion glycoprotein Victoria A. Avanzato, NIAID, NIH 2:00 – 2:35 PM Lessons from novel viruses in infection and immunity David Wang, Ph.D., Washington University School of Medicine in St. Louis 2:35 – 3:10 PM Assessing the evolutionary potential of SARS-CoV-2 Jesse Bloom, Ph.D., Fred Hutchinson Cancer Research Center 3:10 – 3:15 PM Closing Remarks Paolo Lusso, M.D., Ph.D., NIAID, NIH The 2020 Norman P. Salzman Memorial Postdoctoral Fellow Award in Basic and Clinical Virology Kizzmekia S. Corbett, Ph.D. Viral Pathogenesis Laboratory Vaccine Research Center, NIAID, NIH Dr. Kizzmekia S. Corbett is a research fellow in the Viral Pathogenesis Laboratory at the National Institutes of Health, National Institute of Allergy and Infectious Diseases, Vaccine Research Center, where she works under the direction of the VRC’s Deputy Director, Dr. Barney S. Graham. She received a BS in Biological Sciences, with a secondary major in Sociology, in 2008 from the University of Maryland – Baltimore County, where she was a Meyerhoff Scholar and a NIH undergraduate scholar. She then obtained a PhD in Microbiology and Immunology from the University of North Carolina at Chapel Hill School of Medicine in 2014. A viral immunologist by training, her current work propels development of novel coronavirus vaccines and antibody therapies, including mRNA-1273, a leading candidate vaccine against the virus that causes COVID-19. In all, she has fifteen years of expertise studying dengue virus, respiratory syncytial virus, influenza virus, and coronaviruses. Along with her research activities, Dr. Corbett is an active member of the NIH Fellows Committee and avid advocator of STEM education and vaccine awareness in underserved communities. Combining her research goals with her knack for mentoring, Dr. Corbett aims to become an independent principal investigator. The 2020 Norman P. Salzman Memorial Mentor of Postdoctoral Fellow Award in Basic and Clinical Virology Barney S. Graham, M.D., Ph.D. Deputy Director, Vaccine Research Center, NIAID, NIH Chief, Viral Pathogenesis Laboratory Dr. Graham is Deputy Director and Chief of the Viral Pathogenesis Laboratory at the NIAID Vaccine Research Center. He has a BA from Rice University, an MD from the University of Kansas School of Medicine, and a PhD in Microbiology & Immunology from Vanderbilt University School of Medicine where he also completed Internal Medicine residency, chief residencies, and a fellowship in Infectious Diseases. His primary interests are vaccine development for viral diseases, viral pathogenesis, and mechanisms of immunity and pandemic preparedness. He currently directs basic laboratory research, contributes to the pipeline of new VRC vaccines, and provides oversight of candidate VRC vaccines and antibodies in advanced development including those for HIV, Ebola, and Chikungunya. His laboratory explores the structural basis for antibody-mediated viral neutralization, investigates basic mechanisms by which T cells affect viral clearance and immunopathology, and has developed novel vaccines for RSV, influenza, Zika, and coronaviruses including the first COVID-19 vaccine and monoclonal antibody products to enter clinical testing. The 2020 Norman P. Salzman Memorial Graduate Student Award in Basic and Clinical Virology Victoria A. Avanzato Virus Ecology Section, Laboratory of Virology, NIAID, NIH Vicky received her B.S. degrees in Immunology and Infectious Disease, and Toxicology, from The Pennsylvania State University, Schreyer Honors College, in 2015. She is currently pursuing her MD and PhD degrees through the NIH Oxford-Cambridge Scholars program and Emory University School of Medicine. Her dissertation research focuses on characterizing neutralizing epitopes on the Nipah virus surface glycoproteins using a combination of structural biology and animal models under the supervision of Vincent J. Munster (NIH) and Thomas A. Bowden (University of Oxford). She has also optimized serology assays to study the antibody response to SARS-CoV-2 infection and vaccination, and studied the long-term shedding of infectious SARS-CoV-2 from an immunocompromised patient. After the completion of her MD/PhD training, Vicky plans to become an infectious disease physician, while continuing to research antibody responses to emerging viral pathogens and global health. The 2020 Norman P. Salzman Memorial Mentors of Graduate Student Award in Basic and Clinical Virology Vincent Munster, Ph.D. Dr. Thomas Bowden Chief Virus Ecology Section, Rocky Mountain Division of Structural Biology, Wellcome Centre Laboratories, NIAID, NIH for Human Genetics, University of Oxford Dr. Vincent Munster is the chief of Dr. Thomas Bowden is an MRC the Virus Ecology Section at NIAIDs Senior Non-Clinical Research Rocky Mountain Laboratories. He Fellow in the Division of Structural received his Ph.D. in virology from Biology, Wellcome Centre for Erasmus University, Rotterdam, Human Genetics, University of the Netherlands, in 2006. During Oxford. Prior to becoming a his Ph.D. studies, Dr. Munster Principal Investigator, he studied studied the ecology, evolution, and emerging viruses at Scripps pathogenesis of avian influenza Research, the University of St viruses. He continued his training Andrews, and the University of at the Erasmus Medical Center Oxford as a Sir Henry Wellcome from 2006 to 2009, where he Post-doctoral Fellow. His worked within the Center for Research on Influenza Pathogenesis laboratory utilizes methods in structural biology to provide and Surveillance (CRIPS) focusing on pathogenicity and human-to- molecular-level insights into RNA virus glycoprotein architecture human transmission of influenza A viruses. Dr. Munster joined the and functionality. He has a particular interest in the host- NIAIDs Laboratory of Virology as a visiting fellow in 2009 to study interactions of emerging RNA viruses, such as Rift Valley fever virus, the ecology of emerging viruses such as Ebola virus. In 2013, Dr. Nipah virus, and hantaviruses, and applying structural information Munster established the Virus Ecology Unit as an independent to inform vaccine and antiviral development. tenure-track investigator. His lab is working to elucidate the ecology of emerging viruses and drivers of zoonotic and cross- species transmission. The lab uses a combined field and experimental research approach and conducts research at the state-of-the-art high- and maximum-containment facilities of the Rocky Mountain Laboratories, as well as at field study sites in Africa (the Republic of the Congo, Mali, Ghana, Liberia) and the Middle East (Jordan).
Load more

Recommended publications
  • Construction and Characterization of an Infectious Vaccinia Virus And
    Proc. Nat. Acad Sci. USA Vol. 80, pp. 7155-7159, December 1983 Biochemistry Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters (hybrid vaccinia virus/chimeric gene/live virus vaccine/recombinant DNA) GEOFFREY L. SMITH*, BRIAN R. MURPHYt, AND BERNARD MOSS* *Laboratory of Biology of Viruses and tLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20205 Communicated by Robert M. Chanock, August 29, 1983 ABSTRACT A DNA copy of the influenza virus hemagglu- striction sites for the insertion of the foreign gene segment (6, tinin gene, derived from influenza virus A/Jap/305/57 (H2N2) 7). was inserted into the genome of vaccinia virus under the control In this communication, we describe the formation and prop- of an early vaccinia virus promoter. Tissue culture cells infected erties of a vaccinia virus recombinant that contains the influ- with the purified recombinant virus synthesized influenza hem- enza virus gene for hemagglutinin (HA). The HA genes from agglutinin, which was glycosylated and transported to the cell sur- several influenza subtypes have been cloned and their se- face where it could' be cleaved with trypsin into HAI and HA2 quences determined (14-18), and some of these been ex- subunits. Rabbits and hamsters inoculated intradermally with re- have combinant virus produced circulating antibodies that inhibited pressed in simian virus 40 (SV40) virus vectors (19-22). The hemagglutination by influenza virus. Furthermore, vaccinated product-of this gene is probably the most thoroughly studied hamsters achieved levels of antibody similar to those obtained upon integral membrane protein: its three-dimensional structure has primary infection with influenza virus and were protected against been determined (23), antigenic sites have been mapped (24), respiratory infection with the A/Jap/305/57 influenza virus.
    [Show full text]
  • T. Franklin Williams Scholars Program
    Developing a New Generation of Medical Subspecialists with Expertise in Aging and Care of the Elderly T. Franklin Williams Scholars Program Report to T. Franklin Williams Scholars Program Evaluation Team ASP Geriatrics Steering Committee Integrating Geriatrics Project Evaluation Team May 2011 Submitted by: Erika D. Tarver Project Administrator Association of Specialty Professors 330 John Carlyle Road Suite 610 Alexandria, VA 22314 T: (703) 341-4540 F: (703) 519-1890 [email protected] Kevin P. High, MD Principal Investigator William R. Hazzard, MD Co-Principal Investigator Table of Contents Narrative Progress Report Application and Award Progress Summary of Success of T. Williams Scholars Program Appendices A. 2008 Scholars 24-Month Progress Reports Neena S. Abraham, MD (Note: This is Dr. Abraham’s final report) Steven G. Coca, DO Jeffrey G. Horowitz, MD Danelle F. James, MD Heidi Klepin, MD George C. Wang, MD 2009 Williams Scholars Progress Reports and Summary of 18-Month Questionnaire B. Peter Abadir, MD 12-month Progress Report C. Kathleen M. Akgun, MD 12-Month Progress Report Publication D. Alison Huang, MD 12-Month Progress Report Publication E. Eswar Krishnan, MD 12-Month Progress Report Publication F. Rohit Loomba, MD Publication G. Sharmilee Nyenhuis, MD 12-Month Progress Report Publication H. Peter P. Reese, MD 12-Month Progress Report Publication I. Erik B. Schelbert, MD 12-Month Progress Report Publication J. Helen Keipp Talbot, MD 12-Month Progress Report Publication K. Summary of 18-Month Questionnaire 2010 Williams Scholars Mentor Interviews and Summary of Six-Month Questionnaire L. Kellie Hunter-Campbell, MD Six-Month Mentor Interview M.
    [Show full text]
  • SARS-Cov-2 Protein Subunit Vaccination Elicits Potent Neutralizing Antibody Responses
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.31.228486; this version posted July 31, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses Marco Mandolesi1,*, Daniel J. Sheward1,2,*, , Leo Hanke1, Junjie Ma1, Pradeepa Pushparaj1, Laura Perez Vidakovics1, Changil Kim1, Karin Loré3, Xaquin Castro Dopico1, Jonathan M. Coquet1, Gerald McInerney1, Gunilla B. Karlsson Hedestam1,†, , and Ben Murrell1,†, 1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden 2Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa 3Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden *These authors contributed equally †These authors contributed equally The outbreak and spread of SARS-CoV-2 (Severe Acute Res- Results piratory Syndrome coronavirus 2), the cause of coronavirus dis- ease 2019 (COVID-19), is a current global health emergency and To evaluate the use and immunogenicity of recombinant a prophylactic vaccine is needed urgently. The spike glycopro- protein subunit vaccines for SARS-CoV-2 we immunized tein of SARS-CoV-2 mediates entry into host cells, and thus is a C57BL/6J mice (N=24) with either the spike ectodomain or target for neutralizing antibodies and vaccine design. Here we RBD, expressed in 293-F cells. The RBD domain was ex- show that adjuvanted protein immunization with SARS-CoV-2 pressed as an Fc-fusion protein, which was cleaved and the 1 spike trimers, stabilized in prefusion conformation , results in RBD subsequently purified by size-exclusion chromatogra- potent antibody responses in mice and rhesus macaques with phy.
    [Show full text]
  • Vaccinia Virus and Poxvirology M E T H O D S I N M O L E C U L a R B I O L O G Y™
    METHODS IN MOLECULAR BIOLOGY BIOLOGYTMTM Volume 269 VVacciniaaccinia VirusVirus andand PoxvirologyPoxvirology MethodsMethods andand ProtocolsProtocols Edited by Stuart N. Isaacs Vaccinia Virus and Poxvirology M E T H O D S I N M O L E C U L A R B I O L O G Y™ John M. Walker, SERIES EDITOR 291. Molecular Toxicology Protocols, edited by 270. Parasite Genomics Protocols, edited by Sara Phouthone Keohavong and Stephen G. Grant, E. Melville, 2004 2005 269. Vaccina Virus and Poxvirology: Methods 290. Basic Cell Culture, Third Edition, edited by and Protocols,edited by Stuart N. Isaacs, 2004 Cheryl D. Helgason and Cindy Miller, 2005 268. Public Health Microbiology: Methods and Protocols, edited by John F. T. Spencer and 289. Epidermal Cells, Methods and Applications, Alicia L. Ragout de Spencer, 2004 edited by Kursad Turksen, 2004 267. Recombinant Gene Expression: Reviews and 288. Oligonucleotide Synthesis, Methods and Appli- Protocols, Second Edition, edited by Paulina cations, edited by Piet Herdewijn, 2004 Balbas and Argelia Johnson, 2004 287. Epigenetics Protocols, edited by Trygve O. 266. Genomics, Proteomics, and Clinical Tollefsbol, 2004 Bacteriology: Methods and Reviews, edited 286. Transgenic Plants: Methods and Protocols, by Neil Woodford and Alan Johnson, 2004 edited by Leandro Peña, 2004 265. RNA Interference, Editing, and 285. Cell Cycle Control and Dysregulation Modification: Methods and Protocols, edited Protocols: Cyclins, Cyclin-Dependent Kinases, by Jonatha M. Gott, 2004 and Other Factors, edited by Antonio Giordano 264. Protein Arrays: Methods and Protocols, and Gaetano Romano, 2004 edited by Eric Fung, 2004 284. Signal Transduction Protocols, Second Edition, 263. Flow Cytometry, Second Edition, edited by edited by Robert C.
    [Show full text]
  • Journal Pre-Proof
    Journal Pre-proof Neutralizing monoclonal antibodies for COVID-19 treatment and prevention Juan P. Jaworski PII: S2319-4170(20)30209-2 DOI: https://doi.org/10.1016/j.bj.2020.11.011 Reference: BJ 374 To appear in: Biomedical Journal Received Date: 2 September 2020 Revised Date: 6 November 2020 Accepted Date: 22 November 2020 Please cite this article as: Jaworski JP, Neutralizing monoclonal antibodies for COVID-19 treatment and prevention, Biomedical Journal, https://doi.org/10.1016/j.bj.2020.11.011. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Chang Gung University. Publishing services by Elsevier B.V. TITLE: Neutralizing monoclonal antibodies for COVID-19 treatment and prevention Juan P. JAWORSKI Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina Instituto Nacional de Tecnología Agropecuaria, Buenos Aires, Argentina KEYWORDS: SARS-CoV-2, Coronavirus, Monoclonal Antibody, mAb, Prophylaxis, Treatment CORRESPONDING AUTHOR: Dr. Juan Pablo Jaworski, DVM, MSc, PhD. Consejo Nacional de Investigaciones Científicas y Técnicas Instituto de Virología, Instituto Nacional de Tecnología Agropecuaria Las Cabañas y de los Reseros (S/N), Hurlingham (1686), Buenos Aires, Argentina Tel / Fax: 054-11-4621-1447 (int:3400) [email protected] ABSTRACT The SARS-CoV-2 pandemic has caused unprecedented global health and economic crises.
    [Show full text]
  • Recent Zoonotic and Vector-Borne Viral Threats NIAID Vaccine
    4/1/2020 PROTOTYPE PATHOGEN APPROACH TO PANDEMIC PREPAREDNESS HIV→PNEUMOVIRUS→PARAMYXOVIRUS→CORONAVIRUS ADVAC Alumni 2 April 2020 Barney S. Graham, MD, PhD Deputy Director Vaccine Research Center, NIAID, NIH 1 Recent Zoonotic and Vector-borne Viral Threats • Hanta virus • Nipah/Hendra • West Nile virus • SARS • Influenza • Chikungunya • Ebola • MERS • Zika • EV‐D68 • SARS‐CoV‐2 2 NIAID Vaccine Research Center Basic Research Process Development Nucleic acid Vectors VLPs • AIDS/HIV • Influenza Proteins and cGMP Manufacturing nanoparticles • Ebola/Marburg • RSV • Malaria Monoclonal antibodies • Tuberculosis • EID GLP Analysis • West Nile virus, Zika • Chikungunya • W/E/V equine encephalitis viruses • MERS‐CoV, SARS, and other CoV • Nipah and other paramyxoviruses • EV‐D68 and other picornaviruses Clinical Trials • Smallpox 3 1 4/1/2020 Public health burden of re-emerging & emerging viruses Traditional Approaches • Licensed vaccines/antibiotics Vaccine • Passive surveillance Challenges • Contact tracing • Quarantine • Vaccines for unmet needs • Emerging viruses • Improving licensed vaccines 4 4 New Technologies are Transforming Vaccinology • Structure-based vaccine design Structural analysis of antigenic sites on viral • Single-cell sorting, sequencing, and bioinformatics surface glycoproteins – Rapid isolation of human mAbs Isolation of human monoclonal – Definition of antibody lineages antibodies from single B cells – Analysis of immune responses • Protein engineering of self-assembling nanoparticles • Rapid DNA synthesis • Recombinant
    [Show full text]
  • Proposed Minutes
    Approved 07/19/2021 MINUTES ST. CLAIR SHORES CITY COUNCIL MEETING JUNE 21, 2021 Regular Meeting of the City Council, held in the Council Chambers, located at 27600 Jefferson Avenue., St. Clair Shores, Michigan. Present: Mayor Kip C. Walby, Council Members Peter Accica, John Caron, Ron Frederick, David Rubello, Candice Rusie and Chris Vitale Also Present: City Manager Matthew Coppler, City Clerk Mary Kotowski, Deputy City Clerk Abby Hauff, Directors Henry Bowman, Chris Rayes and Laura Stowell and City Attorney Robert Ihrie 1. CALL TO ORDER, ROLL CALL AND PLEDGE OF ALLEGIANCE Mayor Walby called the meeting to order at 7:00 p.m. Ms. Kotowski, City Clerk, called the roll, and a quorum was present. The Pledge of Allegiance was recited. Mayor Walby introduced Abby Hauff, the new Deputy City Clerk, and she said a few words. 2. PROCLAMATIONS & PRESENTATIONS a. Memorial Day Parade Trophy Presentation Cheryl Furdos, Memorial Day Parade Committee Chairperson, and Mayor Walby presented trophies to the following winners: The Best Color Guard - U.S. Air Force Honor Guard; The Best Special Entry - Eddie Munster and the Munster Koach; The Best Patriotic Float - Viviano Flower Shop; The Best Band - 338th Army Band; The Best School Band - Lakeview Marching Band; The Best Overall Float - SCS Baseball & Softball Association and Lac Ste. Claire Kiwanis, which was also the Mayor’s Choice; The Best Overall Entry - The Arsenal of Democracy Museum; and the Chairwoman’s Choice - Cub Scout Pack #2018. b. Dr. Jason McLellan Proclamation Mayor Walby presented the following proclamation to Mr. and Mrs. McLellan who were present on behalf of their son Dr.
    [Show full text]
  • HIV?AIDS Researchers at the NIH Clinical Center
    The NIH Clinical Center treats a diverse group of patients from all over the world. It also draws researchers from different cultures and backgrounds. Learn more about some of the many researchers who conduct their work on the human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) at the Clinical Center. Thomas C. Quinn, M.D., M.Sc., conducts research for the National Institute of Allergy and Infectious Diseases at the NIH Clinical Center. He is a senior investigator and chief of the International HIV/STD Section of the Laboratory of Immunoregulation. Dr. Quinn obtained his M.D. from Northwestern University. He was a research associate in infectious diseases in the NIAID Laboratory of Parasitic Diseases and completed a fellowship in infectious diseases at the University of Washington. Since 1981, he has been assigned to the division of infectious diseases at Johns Hopkins University, where he became a professor of medicine in 1991. Dr. Quinn is a member of the Institute of Medicine and the National Academy of Sciences and is a fellow of the American Association for the Advancement of Science. His major areas of research are: Definition of epidemiologic features of HIV-1 and HIV-2 infections in developing countries and the United States Assessment of biomedical interventions to control HIV, including circumcision, prevention of mother-to-child transmission, pre-exposure prophylaxis, and vaccine development Assessment of the frequency of Chlamydia trachomatis infections in selected populations using noninvasive sensitive nucleic-acid amplification assays for diagnosis Evaluations of interventions to control blinding trachoma due to Chlamydia trachomatis in sub-Saharan Africa See the full program description.
    [Show full text]
  • Poxvirus DNA Replication
    Downloaded from http://cshperspectives.cshlp.org/ on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press Poxvirus DNA Replication Bernard Moss Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 Correspondence: [email protected] Poxviruses are large, enveloped viruses that replicate in the cytoplasm and encode proteins for DNA replication and gene expression. Hairpin ends link the two strands of the linear, double-stranded DNA genome. Viral proteins involved in DNA synthesis include a 117-kDa polymerase, a helicase–primase, a uracil DNA glycosylase, a processivity factor, a single- stranded DNA-binding protein, a protein kinase, and a DNA ligase. A viral FEN1 family protein participates in double-strand break repair. The DNA is replicated as long conca- temers that are resolved by a viral Holliday junction endonuclease. oxviruses are large, enveloped, DNA viruses (Moss 2007). The DNA replication proteins, in Pthat infect vertebrate and invertebrate spe- contrast to those involved in early transcription, cies and replicate entirely in the cytoplasm are not packaged in virions but are translated (Moss 2007). Two poxviruses are human-spe- from viral early mRNAs. DNA replication oc- cific: variola virus and molluscum contagiosum curs following release of the genome from the virus. The former causes smallpox, a severe dis- core, and progeny DNA serves as the template ease with high mortality that was eradicated for transcription of intermediate- and late-stage more than two decades ago; the latter is distrib- genes (Yang et al. 2011). uted worldwide and produces discrete benign skin lesions in infants and extensive disease in immunocompromised individuals.
    [Show full text]
  • Kizzmekia S. Corbett
    KIZZMEKIA S. CORBETT, PHD Senior Research Fellow National Institutes of Health | National Institute of Allergy and Infectious Diseases | Vaccine Research Center 40 Convent Drive, Building 40 - Room 2608, Bethesda MD 20892 [email protected] | phone: 301.761.7610 | fax: 301.480.2771 EDUCATION Doctor of Philosophy in Microbiology and Immunology 2014 University of North Carolina at Chapel Hill (UNC) Director’s Scholar Bachelor of Science in Biological Sciences | Secondary Major in Sociology 2008 University of Maryland – Baltimore County (UMBC) Robert and Jane Meyerhoff Scholar RESEARCH EXPERIENCE Research Fellow 10/14 - present National Institutes of Health | Vaccine Research Center | PI: Barney S. Graham, MD PhD Research Interest: mechanisms of viral immunity to inform influenza and coronavirus vaccine development Graduate Research Assistant 08/09 – 10/14 University of North Carolina at Chapel Hill | Microbiology and Immunology | PI: Aravinda de Silva, MPH PhD Research Interest: human antibody responses to dengue virus infection Visiting Scholar 04/14 – 05/14 Genetech Research Institute | PI: Aruna Dharshan de Silva, PhD Research Interest: immunological relevance of dengue virion maturation Postbaccalaureate Research Fellow 05/08 – 08/09 National Institutes of Health | Vaccine Research Center | PI: Barney S. Graham, MD PhD Research Interest: novel vaccine platform design for respiratory syncytial virus antigens NIH Undergraduate Scholarship Program Summer Intern 06/07 – 08/07 National Institutes of Health | Vaccine Research Center
    [Show full text]
  • That Record-Breaking Sprint to Create a COVID-19 Vaccine The
    NATIONAL INSTITUTES OF HEALTH • OFFICE OF THE DIRECTOR | VOLUME 29 ISSUE 5 • SEPTEMBER-OCTOBER 2021 That Record-breaking The Intersection of Man and Machine Sprint to Create a Bionics Gives New Hope to Those Living With Physical Disabilities COVID-19 Vaccine BY MICHAEL TABASKO, OD BY MELISSA GLIM At the end of 2019, most people were looking forward to an exciting 2020, a new decade starting with those magic numbers, 20-20, that denote a sharpness of vision. There would be the Summer Olympics in Japan and the U.S. presidential election. Meanwhile, intramural scientists at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC) were designing vaccines for several coronaviruses using a promising, new platform based on messenger RNA (mRNA). Everything changed on a Saturday morning in early January. Chinese scientists CREDIT: TH0MAS BULEA (LEFT); NIH CLINCAL CENTER (RICHT) had isolated a new coronavirus that was (Left) The NIH pediatric exoskeleton for children with cerebral palsy and other movement disorders uses custom actuators causing a serious epidemic in China’s Wuhan from Agilik developed as part of a cooperative research and development agreement with NIH, along with embedded sensors and microcontrollers, to provide overground gait training while worn. (Right) Alexander Theodorakos, a participant province and released its genetic sequence to in a research protocol at the NIH Clinical Center that is evaluating the new pediatric exoskeleton, and Thomas Bulea, the the scientific community around the world. study’s principal investigator, discuss how the device changes the way the legs move when walking. Barney Graham, director of the VRC’s Viral Pathogenesis Laboratory (VPL), and If popular culture is any indication, the notion that bionic technology will VRC research fellow Kizzmekia Corbett someday redefine the boundaries of human function has long held our collective dropped everything and began using this fascination.
    [Show full text]
  • Nci-Plan-2013.Pdf
    THE NATIONAL CANCER PROGRAM MANAGING THE NATION’S RESEARCH PORTFOLIO AN ANNUAL PLAN AND BUDGET PROPOSAL FOR FISCAL YEAR 2013 National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Contents 1 Foreword 4 Provocative Questions 8 Center for Cancer Genomics 16 Introduction to Cancer Profiles 18 Pancreatic Ductal Adenocarcinoma 22 Colorectal Cancer 26 B-Cell Lymphoma 30 Renal Cell (Kidney) Cancer 34 GI Stromal Cancer 39 Research Focus: Comorbidities 42 Research Focus: Circulating Tumor Cells 44 Research Focus: Reducing Cancer Health Disparities 50 The Frederick National Laboratory for Cancer Research 61 Small Business Innovation Research, Small BusinessTechnology Transfer (SBIR, STTR) 66 NCI Center for Global Health 72 NCI-Designated Cancer Centers 83 Glossary of Terms 84 Budget FOREWORD The National Cancer Program MANAGING THE NATION’S RESEARCH PORTFOLIO his year marks the 75th anniversary of the founding of the National Cancer Institute, the first so-called “categorical institute” of what has become the National Institutes of Health, with its 27 Institutes and Centers. Over the years, the Congress and the public have generously supported the TNCI—and the NIH generally—with sustained budgetary increases. This was especially true for the NCI during the rapid expansion of its budget following the National Cancer Act of 1971 and for the NIH, including the NCI, during the 5-year doubling of its budget, launched in 1998. Both of these eras of rapid growth were remarkably fruitful. The first launched the pursuit of cancer genes and the molecular basis of oncogenesis, laying the foundation for the transformation of clinical oncology that is now occurring.
    [Show full text]